Endpoint scale total scores (150 mg twice daily dose) (Scales of sexual functioning. As studies used different scales to assess sexual functioning, differences are expressed as standardised mean differences (SMD)) · people with antidepressant‐induced sexual dysfunction
1 finding from 1 review
Effect on later sexual function · people with antidepressant‐induced sexual dysfunction
Bupropion showed no clear difference in 50% reduction in score on the Arizona Sexual Experiences Scale… compared with placebo (moderate certainty).
1 finding from 1 review
Dropout · people with antidepressant‐induced sexual dysfunction
Bupropion showed no clear difference in dropouts (People leaving the trial early) compared with placebo (high certainty).
1 finding from 1 review
Incidence of SAD (SIGH‐SAD score ≥ 20) ( · adults with a history of SAD who do not fulfil criteria for major depressive disorder
Bupropion XL probably leads to lower incidence of SAD (SIGH‐SAD score ≥ 20) compared with placebo (moderate certainty).
1 finding from 1 review
Overall rate of adverse events · adults with a history of SAD who do not fulfil criteria for major depressive disorder
Bupropion XL showed no clear difference in overall rate of adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Headache · adults with a history of SAD who do not fulfil criteria for major depressive disorder
Bupropion XL probably leads to higher headache compared with placebo (moderate certainty).
1 finding from 1 review
Insomnia · adults with a history of SAD who do not fulfil criteria for major depressive disorder
Bupropion XL may leads to higher insomnia compared with placebo (low certainty).
1 finding from 1 review
Nausea · adults with a history of SAD who do not fulfil criteria for major depressive disorder
Bupropion XL may leads to higher nausea compared with placebo (low certainty).
1 finding from 1 review
Diarrhoea · adults with a history of SAD who do not fulfil criteria for major depressive disorder
Bupropion XL showed no clear difference in diarrhoea compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · adults with a history of SAD who do not fulfil criteria for major depressive disorder
Bupropion XL showed no clear difference in discontinuation due to adverse events compared with placebo (low certainty).
1 finding from 1 review
Failure to respond at endpoint (6‐12 weeks) · patients with depression
Paroxetine showed no clear difference in failure to respond at endpoint (6‐12 weeks) compared with bupropion (moderate certainty).
1 finding from 1 review
Failure to respond at 1‐4 weeks · patients with depression
1 finding from 1 review
Failure to respond at 16‐24 weeks · patients with depression
1 finding from 1 review
Failure to remit at endpoint · patients with depression
1 finding from 1 review
SMD at endpoint · patients with depression
1 finding from 1 review
Failure to complete ‐ any cause ‐ · patients with depression
Paroxetine showed no clear difference in failure to complete ‐ any cause ‐ compared with bupropion (moderate certainty).
1 finding from 1 review
Participants with at least some Side Effects · patients with depression
Paroxetine showed no clear difference in participants with at least some Side Effects compared with bupropion (moderate certainty).
1 finding from 1 review
Failure to respond (reduction ≥ 50% on HDRS) · patients with depression
Fluoxetine showed no clear difference in failure to respond (reduction ≥ 50% on HDRS) compared with bupropion (moderate certainty).
1 finding from 1 review
Endpoint score (HDRS or MADRS) · patients with depression
1 finding from 1 review
Failure to complete ‐ total ‐ · patients with depression
Fluoxetine showed no clear difference in failure to complete ‐ total ‐ compared with bupropion (moderate certainty).
1 finding from 1 review